Gliomas are the most common type of central nervous system cancer but how these tumors develop is not fully understood. Sheri Holmen, PhD a researcher at Huntsman Cancer Institute (HCI) and professor of surgery at the University of Utah just published the results of her research on gliomas in Cell Reports. The work is focused on a mutated gene that is a critical piece of the puzzle for glioma development, according to Holmen’s work.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.
New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) indicates steroid and hormone receptors are simultaneously active in many endometrial cancer tissues. The findings, published today in the journal Cell Reports, yield insights about factors that contribute to more aggressive endometrial tumors.
The Board of Directors of Huntsman Cancer Foundation has elected Peter R. Huntsman as Chairman of the Board effective immediately. He replaces his father, Jon M. Huntsman, Sr., who founded Huntsman Cancer Institute (HCI) and was its principal benefactor. Jon M. Huntsman passed away earlier this month.
New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) illuminates aspects of how an early embryo, the product of fertilization of a female egg cell by a male sperm cell, can give rise to all the many cell types of the adult animal. The findings, published today in the journal Cell, have significant implications for understanding how early development is orchestrated, and provides a mechanism for how parental environment might impact the expression of these genes in the offspring.
A new lighting installation at Huntsman Cancer Institute (HCI) at the University of Utah honors Jon M. Huntsman’s enduring impact on cancer research and care. The installation, called ‘The Beacon of Hope’ is located within an architectural feature on the west facade of the original HCI research building, and is viewable from the exterior of the building. The newly-designed installation will be lit for the first time at sunset on Friday, February 9, to commemorate weekend memorial services for Huntsman.
Funeral services for Jon M. Huntsman, will be held on Saturday, February 10, at 11:00 a.m. in the Jon M. Huntsman Center on the campus of the University of Utah, 1825 E. South Campus Drive, Salt Lake City.
We are truly saddened at the passing of our remarkable founder and benefactor, Jon M. Huntsman, this afternoon. He passed away peacefully at home, surrounded by his loving family. Other than his family, his greatest passion was to eradicate cancer. We will honor his legacy by continuing to provide hope and healing to all impacted by this disease.
Researchers have identified two gene regions that contribute to multiple myeloma, an inherited cancer that occurs in bone marrow, through a new method that makes use of human disease pedigrees. Nicola Camp and Rosalie Waller of Huntsman Cancer Institute at the University of Utah and colleagues report their findings February 1st in PLOS Genetics.
Huntsman Cancer Institute (HCI) at the University of Utah has been awarded a $2.4 million, two-year grant from the National Cancer Institute (NCI) to help continue its research in breast cancer. Alana Welm, PhD and Bryan Welm, PhD, investigators at HCI, along with Michael Lewis, PhD, a colleague at Baylor College of Medicine, will use this new funding to serve as a Breast Cancer Patient-derived xenograft Development and Trials Center (PDTC) to research and test new drugs for breast cancer. This new Center is only one of four such Centers in the nation.
Researchers developed a new mathematical tool to validate and improve methods used by medical professionals to interpret results from clinical genetic tests. The work was published this month in Genetics in Medicine.
The research was led by Sean Tavtigian, PhD, a cancer researcher at Huntsman Cancer Institute (HCI) and professor of oncological sciences at the University of Utah, in collaboration with genetics experts from around the United States.
Mary Beckerle, PhD, CEO and Director of Huntsman Cancer Institute (HCI) at the University of Utah, is this year’s recipient of the Alfred G. Knudson Award in Cancer Genetics from the National Cancer Institute (NCI).
A new cancer treatment technology is one step closer to Salt Lake City. Today Huntsman Cancer Institute (HCI) at the University of Utah (U of U) announced a plan to add a proton therapy center to its Cancer Hospital. The center will be the only one of its kind in the region. The plan will now move forward to the next steps of approval, design and vendor selection.
Saundra Buys, MD, medical oncologist at Huntsman Cancer Institute (HCI) and a professor of medicine at the University of Utah was named by Forbes among the top breast cancer physicians in the country. Buys is one of only 27 in the nation to receive this recognition.
Each year over 1,000 adolescents and young adults (AYAs) in Utah are diagnosed with cancer. For many of these young adults (ages 15-39), the cancer diagnosis is their first real medical issue. Patients may suddenly have to learn the difference between a medical oncologist and a radiation oncologist. They may also have questions about fertility issues, or need help understanding the complexities of the healthcare system. To help guide patients through these tough issues Huntsman Cancer Institute (HCI) at the University of Utah, in collaboration with Intermountain Healthcare, offers a patient navigator designed to meet the needs of AYA cancer patients.
A new study by researchers at Huntsman Cancer Institute (HCI) at the University of Utah observed how breast cancer tumors evolve over time and demonstrated how changes within tumors may contribute to the process by which cancers no longer respond to treatment. Further, the research identifies that some of these changes may be shared across certain treatment-resistant breast cancers. The study was published this month in Nature Communications.
Risk for aging-related diseases such as heart disease and diabetes was significantly higher among thyroid cancer survivors in Utah than it was among age-matched, cancer-free individuals, with those diagnosed before age 40 having the highest risk for some of the diseases, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research
All cancer treatments and medications that are used today, at one point, were clinical trials. Clinical trials can offer hope, particularly in a complex disease like cancer. But getting access to clinical trials can be difficult, especially if patients have to travel a long distance to a hospital that offers trials.
People with an inherited syndrome called familial adenomatous polyposis (FAP) have a 100% lifetime risk of developing colorectal cancer if they do not seek appropriate medical care. Recent findings published by researchers at Huntsman Cancer Institute at the University of Utah identified a promising prevention treatment for patients with FAP.
When she was first diagnosed with ovarian cancer, Dr. Jan Byrne didn't know of any survivors of the disease.
"It's a devastating disease — a silent killer," she said. "A lot of people don't make it."
Byrne's cancer was found in the early stages, however, and after six months of chemotherapy and three major surgeries at Huntsman Cancer Institute, she survived.
It's been six years.